tralokinumab is an approved drug (EMA & FDA (2021))
Compound class:
Antibody
Comment: Tralokinumab is a monoclonal antibody directed against interleukin 13 (IL-13), a cytokine secreted by T helper cells, and which is a central mediator of the physiological changes induced by allergic inflammatory reactions [4] Binding affinity of tralokinumab was optimised (aka affinity maturation) using an in vitro ribosome display technology [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| No information available. |
Summary of Clinical Use  |
| Tralokinumab was investigated in clinical trials for efficacy in patienst with uncontrolled asthma, atopic dermatitis, and alopecia areata. Click here to link to ClinicalTrials.gov's listing of Phase 3 tralokinumab trials. In addition, Phase 2 trials evaluated tralokinumab as a treatment for idiopathic pulmonary fibrosis (IPF, NCT01629667 and NCT02036580). Business reports online indicate that AstraZeneca discontinued tralokinumab development for asthma as it showed no benefit over placebo in their STRATOS 2 and TROPOS late-stage asthma trials [1]. The EMA approved LEO Pharma's tralokinumab product Adtralza® in July 2021, as a treatment for severe atopic dermatitis that cannot be controlled by topical drugs. FDA approval for this indication followed at the end of 2021. |
| Mechanism Of Action and Pharmacodynamic Effects |
| IL-13 induces airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion in allergic lung disease such as asthma [3]. These changes contribute to airway obstruction. Tralokinumab was designed to neutralise circulating IL-13, thereby reducing disease symptoms. |
| External links |
|
For extended ADME data see the following: European Medicines Agency (EMA) |
